Format

Send to:

Choose Destination
See comment in PubMed Commons below
Med Clin North Am. 2009 Jan;93(1):223-34, xiii. doi: 10.1016/j.mcna.2008.07.011.

How close are we to having structure-modifying drugs available?

Author information

  • 1Division of Research, New England Baptist Hospital, 125 Parker Hill Avenue, Boston, MA 02120, USA. djhunter@caregroup.harvard.edu

Abstract

This review describes the potential of disease-modifying osteoarthritis drugs (DMOADs), distinguishing between preventing, retarding, stopping, and reversing disease and what might be clinically meaningful. The authors also describe whether there is any evidence to suggest that one can modify disease, and whether the current tissue that is predominantly focused on, namely, cartilage, is an appropriate target. The methodologic approaches and other obstacles to demonstrating efficacy of these agents in clinical trials are considered. This discussion is a narrative review in a field that is rapidly evolving. It is hoped the reader appreciates the complexity of the field and the likely road ahead to DMOAD development.

PMID:
19059031
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk